Background: Infantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin. Among children with trisomy 21 and IESS, treatment with ACTH or oral corticosteroids may yield higher response rates compared with vigabatrin. However, supporting data are largely from single-center, retrospective cohort studies.

Methods: Leveraging the multi-center, prospective National Infantile Spasms Consortium (NISC) database, we evaluated the efficacy of first-line (standard) treatments for IESS in children with trisomy 21. We assessed clinical spasms remission at two weeks, clinical spasms remission at three months, and improvement of EEG (resolution of hypsarrhythmia) three months after initiation of treatment.

Results: Thirty four of 644 (5.3%) children with IESS were diagnosed with trisomy 21. In all children with trisomy 21, epileptic spasms was their presenting seizure type. Twenty of 34 (59%) children were initially treated with ACTH, nine (26%) with oral corticosteroids, and five (15%) with vigabatrin. Baseline demographics did not vary among treatment groups. The overall clinical remission rate after two weeks of treatment was 53% including 13 of 20 (65%) receiving ACTH, three of nine (33%) receiving oral corticosteroids, and two of five (40%) receiving vigabatrin ( = 0.24). The continued clinical response rate at three months was 32% including 8 of 20 (40%) receiving ACTH, two of nine (22%) receiving oral corticosteroids, and one of five (20%) receiving vigabatrin. Thirty of the 34 (88%) children presented with hypsarrhythmia (88%). EEG improvement at three months was better for children treated with ACTH (74%) or oral corticosteroids (83%) than vigabatrin (20%;  = 0.048). Adjustment for time from epileptic spasms onset to treatment did not alter results.

Conclusions: In our cohort, epileptic spasms were the first presenting seizure type in all children with trisomy 21. Among first-line standard treatment options, ACTH may have superior efficacy for clinical and electrographic outcomes for IESS in children with trisomy 21.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11860949PMC
http://dx.doi.org/10.3389/fped.2025.1498425DOI Listing

Publication Analysis

Top Keywords

children trisomy
28
oral corticosteroids
24
epileptic spasms
20
three months
16
first-line standard
12
children
11
infantile epileptic
8
spasms
8
spasms syndrome
8
syndrome children
8

Similar Publications

Human chromosomal anomalies, notably trisomies, disrupt gene expression, leading to diverse cellular and organ phenotypes. Increased cellular senescence (SEN) and oxidative stress in trisomies have gained recent attention. We assessed SEN, senescence-associated secretory phenotype (SASP) and oxidative stress on trisomy 13, 18, and 21 (T13, T18, T21) human fetal lung tissues and isolated primary human fetal lung fibroblasts.

View Article and Find Full Text PDF

Background: There have been an increasing number of publications related to trisomy 18 associated with a shift in the philosophy of care. The objective of this review is to understand the scope of contemporary literature informing the care of children born alive with trisomy 18.

Methods: Included was peer-reviewed, primary literature in MEDLINE, Embase, CINAHL, Scopus, Web of Science, and Cochrane Library from 2012 to 2023 reporting outcomes of children born alive with trisomy 18.

View Article and Find Full Text PDF

Treatment efficacy for infantile epileptic spasms syndrome in children with trisomy 21.

Front Pediatr

February 2025

Division of Pediatric Neurology, Department of Neurology, Johns Hopkins University, Baltimore, MD, United States.

Background: Infantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin. Among children with trisomy 21 and IESS, treatment with ACTH or oral corticosteroids may yield higher response rates compared with vigabatrin.

View Article and Find Full Text PDF

ChromInst: a multicentre evaluation of robustness in aneuploidy and structural rearrangement testing.

J Transl Med

February 2025

Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.

Background: Preimplantation genetic testing for aneuploidy and for chromosomal structural rearrangement (PGT-A/-SR) can improve clinical pregnancy rates and live birth rates, and shorten the time to pregnancy. The large-scale statistics on their efficacy and accuracy across different centres, as well as the frequency of abnormalities for each chromosome, will provide a valuable supplement to previous research.

Methods: Patients who had PGT-A or -SR procedures at five reproductive centres from 2018 to 2022 were recruited based on PGT-A/-SR indications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!